Most side effects on a GLP-1 are miserable and harmless. One is neither. On 29 January 2026 the UK's medicines regulator strengthened the warning that separates the two.
What happened
The MHRA updated the product information for dulaglutide, exenatide, liraglutide, semaglutide and tirzepatide, to reflect the risk of severe acute pancreatitis, including necrotising and fatal cases.
The review behind it covered Yellow Card reports from 2007 to October 2025. There were 1,296 reports of pancreatitis associated with these medicines. Of those, 24 were reported as necrotising pancreatitis and 19 were fatal.
The advice to prescribers is short. Be alert to the risk. Tell patients to seek urgent medical attention if they develop severe and persistent abdominal pain that may radiate to the back and may be accompanied by nausea and vomiting. If pancreatitis is suspected, stop the medicine immediately. If it is confirmed, do not restart it.
How to tell this apart from an ordinary bad day
Nausea on a GLP-1 is common, it usually arrives in the days after a dose or a dose increase, and it fades. Pancreatitis pain is different in three ways, and you do not need to be a doctor to notice them.
It is severe rather than uncomfortable. It persists rather than coming in waves that pass. And it goes through to your back, a band of pain rather than a queasy stomach. It often comes with vomiting that will not settle.
That combination is not a reason to wait and see whether it improves by morning. It is a reason to be seen the same day.
Put this in proportion. Alison Cave, the MHRA's chief safety officer, made the point that for the vast majority of people prescribed them these are safe and effective medicines, and the risk of severe harm is very small. Roughly a thousand reports across eighteen years, against millions of prescriptions, is a rare event. Rare events still need a plan, and the plan is the paragraph above.
What it means for you
Two things, both small. Know the symptom well enough to recognise it at two in the morning without looking it up. And if you have had pancreatitis before, or gallstones, say so before your next dose rather than after it, because that history changes the conversation you should be having with your prescriber.
What to do with this
Medical history is not background detail on this medicine; it changes what a plan is allowed to do. The last question in the calculator asks about pancreatitis, gallbladder disease and the rest, and the answer changes the result.